Reata Pharmaceuticals, Inc.
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (72.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (165.53% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 5,789,158,047
http://www.reatapharma.com
Sec Filling | Patents | 220 employees
(US) Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
education
add to watch list Paper trade email alert is off
Press-releases
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP | $0.204 -0.2% -3.49% 130K
|
Health Technology
|
| O: 5.82%
H: 7.57%
C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published: 2024-01-10 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
NVO | $122.75 -1.43% 0.67% 42K
|
Health Technology
|
| O: -0.33%
H: 0.35%
C: -1.5%
LLY | $745.95 -0.64% -0.13% 17K
|
Health Technology
|
| O: 0.67%
H: 0.85%
C: 0.21%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
ALDX | News | $3.98 0.25% 0.5% 0
|
Health Technology
|
| O: -1.8%
H: 0.46%
C: -2.44%
companies therapeutics growth market
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
| Email alert
Add to watchlist
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published: 2023-11-22 (Crawled : 15:00) - biospace.com/
CNSP | $0.204 -0.2% -3.49% 130K
|
Health Technology
|
| O: 3.35%
H: 25.0%
C: 4.17%
berubicin ongoing pharmaceuticals study
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.55% 0
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
SMMT A | $3.51 -1.68% -1.71% 2
|
Health Technology
|
| O: -0.46%
H: 6.68%
C: -11.75%
PLSE | $7.36 -1.47% -1.36% 20
|
Health Technology
|
| O: 0.39%
H: 6.43%
C: 1.92%
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: -0.82%
H: 0.73%
C: -0.4%
ALNY | News | $145.16 -0.11% -0.19% 1
|
Health Technology
|
| O: 1.06%
H: 2.42%
C: 0.76%
therapeutics financial results
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP | $0.204 -0.2% -3.49% 130K
|
Health Technology
|
| O: -2.8%
H: 18.26%
C: 13.46%
rapid berubicin treatment ongoing glioblastoma study
Biogen Completes Acquisition of Reata Pharmaceuticals
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: -0.02%
H: 1.37%
C: 1.21%
acquisition pharmaceuticals
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.31%
H: 1.04%
C: 0.76%
CNSP | $0.204 -0.2% -3.49% 130K
|
Health Technology
|
| O: -2.46%
H: 2.53%
C: -10.61%
berubicin pharmaceuticals therapy results study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP | $0.204 -0.2% -3.49% 130K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
Biogen to Acquire Reata Pharmaceuticals
Published: 2023-07-28 (Crawled : 11:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 51.72%
H: 1.55%
C: 1.52%
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: 0.19%
H: 1.88%
C: 0.73%
pharmaceuticals acquire
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
XPON | News | $3.15 63.21% 33.9% 100K
|
EGOX | $0.036 12.15% 31.56% 32M
|
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
TPET | $0.3279 -3.56% 23.57% 11M
|
n/a
HOLO | $2.95 31.7% 22.49% 37M
|
WLGS | News | $0.5 15.11% 880K
|
Last 48 Hours Insiders Buying
FNLC P 1275 | $22.16 -0.36% 0.34% 1
|
Finance
|
12:30
ADMQ | $0.0532 -4.14% -40.18% 0
|
|
10:30
AXR P 2400 | $22.17 2.69% 0.0% 0
|
Finance
|
21:00
QCRH P 118 | $55.41 1.34% 1.31% 0
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 3.6K
|
Electronic Technology
|
18:00
RMCF | $3.5501 0.57% 2.22% 0
|
Consumer Non-Durables
|
20:10